Hematopoietic Agents – Sickle Cell Disease Cell and Gene Therapies
Customize your policy alerts
Sign up for Community Health Plan Washington Policy 82.80.40-1 alerts
Get alerted when Policy 82.80.40-1 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing/quantity limits, coding, and authorization rules for the two one-time gene therapies (Casgevy and Lyfgenia) for sickle cell disease with recurrent vaso-occlusive crises/events for Apple Health (Community Health Plan Washington). Also requires treatment centers to be CIBMTR-enrolled per CMS CMMI model.
New policy created
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.